General
Preferred name
INGENOL MEBUTATE
Synonyms
P&D ID
PD098429
CAS
75567-37-2
Tags
natural product
drug
available
Drug Status
approved
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
The pharmacodynamics of ingenol mebutate in producing cell death in actinic keratosis is unknown.
ROE
There is no route of elimination since ingenol mebutate is a topical treatment.
MOA
The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.
HALF-LIFE
There is no half-life quantity since ingenol mebutate is a topical treatment.
INDICATION
For the topical treatment of actinic keratosis.
TOXICITY
The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.
METABOLISM
There is no metabolism of Picato since ingenol mebutate is a topical treatment, and ingenol mebutate does not inhibit or induce a majority of the cytochrome P450 (CYP) enzymes.
ABSORPTION
Since ingenol mebutate is a topical treatment, the systemic absorption is less than 0.1 ng/mL.
MOA
The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.; ;
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
6
Molecular Weight
430.24
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
0
cLogP
2.33
TPSA
104.06
Fraction CSP3
0.68
Chiral centers
8.0
Largest ring
7.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
